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Background: Studies have documented more rapid progression of HCV-associated liver fibrosis in patients co-infected 
with HIV. However, the natural history of HCV infection in both mono-infected and HIV co-infected patients remains 
highly variable. The patterns and predictors of fibrosis progression in the HIV/HCV co-infected population are not 
fully characterized. Given the invasiveness of serial liver biopsies, Fibrosis-4 score (FIB-4), a composite of serum 
biomarkers that correlate well with fibrosis stage, is increasingly used. We used FIB-4 to study the natural history of 
liver fibrosis progression among co-infected patients and evaluated predictors of progression to cirrhosis over 5 years 
prior to treatment with direct acting agents (DAAs). 
Methods:  Study subjects were selected from HIV/HCV co-infected patients receiving care at Yale-New Haven 
Hospital from February 2014 through April 2016 without advanced fibrosis 5 years prior to study entry. Annual FIB-4 
scores dating back 5 years were calculated from the most recent FIB-4 score or the last FIB-4 prior to DAA treatment 
initiation. Baseline demographics and clinical characteristics including HCV genotype, antiretroviral regimen, HIV 
viral loads and CD4 counts were collected. Patients were further categorized based on FIB-4 progression over the 
course of 5 years. Univariate and multivariable logistic regression models were used to examine factors associated with 
FIB-4 progression and a p-value of 0.05 was chosen as the threshold for statistical significance.  
Results:  There were 93 patients evaluated including 65 men and 28 women; mean age of 56.7 years; 32.3% were 
white, 53.8% were black. Injection drug use (IDU) was the major risk factor for HCV acquisition (63.4%) and the most 
common genotype was genotype 1 (81.2%). The median CD4+ count was 564 cells/mm3, and the majority (88.4%) had 
HIV viral loads <50 copies/mL. Over 5 years, 25 (26.9%) had FIB-4 progress to >3.25 and 68 (73.1%) had FIB-4 
remain <3.25. Demographic variables (age, gender, race/ethnicity, BMI, substance use), clinical variables (HIV viral 
load, CD4 count, ART use, HIV duration, HCV duration and viral load) and co-morbid conditions such as diabetes and 
hyperlipidemia did not differ significantly between those whose FIB-4 stayed below 3.25 and those whose FIB-4 
progressed to above 3.25 in univariate and multivariable logistic regression models.   
Conclusion: In this study of 93 HIV/HCV co-infected patients without baseline advanced fibrosis, 26.9% progressed to 
advanced fibrosis over the course of 5 years. We did not identify any statistically significant factors that predicted those 
who were more likely to progress, although clinically relevant factors such as absence of HIV virologic control, low 
CD4 count, and lack of statin use showed a trend towards significance and should be assessed in future studies in a 
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With the advent of combination antiretroviral therapy (cART), HIV infection has 
been transformed from a rapidly fatal disease to a manageable chronic illness. However, 
the threat of opportunistic infections, which were the most frequent cause of mortality in 
the pre-cART era, has been replaced by complications associated with aging and long-
term HIV infection, including cardiovascular disease, lung disease, certain cancers, and 
liver disease. Chronic liver disease is the 2nd leading cause of mortality in the HIV-
infected population, of which the majority are secondary to hepatitis C virus (HCV) 
infection. (1) Liver disease-related deaths have increased markedly in the HIV-infected 
population in the post-cART era, coinciding with the peak of HCV-related disease burden 
epidemiologically. (2)  
It is estimated that of over 33.3 million people living with HIV infection globally, 
approximately 20-30% are co-infected with HCV due to shared routes of disease 
transmission, including parenteral (injection drug use, blood transfusion), perinatal, and 
sexual. (3) The incidence of HIV/HCV coinfection ranges from 10% to over 80% among 
those who acquire HIV by intravenous drug use. (4) Chronic HCV infection is not only 
associated with liver-specific health outcomes such as cirrhosis, liver failure, and 
hepatocellular carcinoma (HCC), but has also been associated with increased 
cardiovascular morbidity, renal dysfunction, insulin resistance, and cancer. (2) Given the 
wide array of adverse health outcomes associated with HCV and its potential as a major 
driver of mortality, treating HIV/HCV coinfected patients should be a critical priority. 
HIV and Liver Disease 
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Although HCV co-infection accounts for much of the liver-related morbidity and 
mortality in HIV-infected individuals, an excess burden of liver disease has been reported 
in HIV mono-infected patients. (1) Liver enzyme elevations are frequently noted in 
patients with HIV, and can not only be attributed to viral hepatitis, but also other causes 
including drug-induced liver injury and both alcoholic and non-alcoholic fatty liver 
disease (NAFLD). Classically, the nucleoside reverse transcriptase inhibitor 
antiretrovirals (NRTIs), have been well studied for their association with hepatotoxicity, 
likely due to direct toxic effect on the hepatocyte mitochondria and resultant break in the 
generation of adenosine triphosphate (ATP) and accumulation of lactic acid. (4) NRTIs 
cause a greater rise in lactic acid and hepatotoxicity compared to HIV protease inhibitors 
(PIs), and are associated with a syndrome of hepatic steatosis. (5, 6) Among PIs, ritonavir 
and ritonavir-boosted regimens have been identified as independent risk factors for the 
development of hepatotoxicity. (4)  
HIV-positive individuals also demonstrate a significant prevalence of NAFLD, 
which is viewed as a hepatic manifestation of metabolic syndrome in the general 
population. Risk factors of obesity, hypertension, insulin resistance, dyslipidemia, and 
diabetes mellitus are prevalent within the HIV population as well. However, HIV-
infected patients are even more prone to NAFLD due to HIV itself, viral hepatitis, or 
ART toxicity. HIV itself can affect lipid profiles, with a higher viral load associated with 
lower LDL cholesterol and higher triglyceride concentrations. (1) Moreover, increased 
intestinal permeability through villous effacement and depletion of CD4 cells increases 
the amount of bacterial lipopolysaccharide reaching the liver and upregulates 
inflammation, accelerating NAFLD. (4) Exposure to ART is an independent risk factor 
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for the development of NAFLD, and insulin resistance and lipodystrophy are associated 
with the use of nucleoside inhibitors and other ART drugs. (4)  
Impact of HCV on HIV Disease 
 The impact of HCV infection on the natural history of HIV progression is unclear. 
Prior to the introduction of cART, there was no difference observed in progression to 
AIDS, death, or decline in CD4+ count between HIV mono-infected and HIV/HCV co-
infected patients. Progression to AIDS did not differ between HCV-positive patients 
acquiring HIV and those with HIV infection alone. (1) However, in the current cART era, 
there is some evidence suggesting that HCV co-infection may affect HIV progression. In 
the Swiss HIV Cohort Study which consisted of patients receiving potent antiretroviral 
therapy, HIV and HCV co-infection were associated with faster progression to AIDS and 
slower CD4+ recovery than in patients with HIV alone. (7) Subsequent meta-analysis 
found decreased CD4+ count recovery after 48 weeks of cART in HIV/HCV co-infected 
patients compared to HIV mono-infected patients. (8) Mechanisms of impaired CD4+ 
count recovery may include chronic immune activation driven by HCV infection leading 
to CD4+ T-cell apoptosis, suppression of CD4+ cell proliferation, and Fas-mediated 
apoptosis due to HCV replication in peripheral blood mononuclear cells and lymphoid 
tissue. (9) 
Impact of HIV on HCV Disease 
It is well-established that HIV modulates the natural history of HCV disease, and 
HIV infection has been associated with higher HCV viral loads and increased risk of 
chronic HCV infection. (10) In a longitudinal cohort of initially HCV mono-infected 
patients, some of whom HIV seroconverted, HCV RNA levels after HIV seroconversion 
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increased 58-fold over the study period, compared with an approximately threefold 
increase in patients who remained HIV negative. (11) Multiple studies have documented 
an association between higher HCV viral load and lower CD4 T cell count in co-infected 
patients, suggesting that cellular immune responses play an important role in control of 
HCV viral replication during chronic HCV infection. (9) HIV is also a prominent risk 
factor for failing to spontaneously clear HCV after acute infection, likely due to the 
impact of HIV infection on effective HCV specific T-cell responses. (12, 13) HIV 
infection may also impair innate immune responses that affect HCV clearance through 
diminished CD4+ stimulation of B-cell responses and antibody production. (9)  
It is well-established that HIV accelerates progression to hepatic fibrosis and 
cirrhosis in HCV co-infected patients. (14) A meta-analysis of 8 separate studies that 
investigated the role of HIV in liver disease in HCV-infected patients found that co-
infected patients had approximately 2 times the risk of cirrhosis diagnosed on liver 
biopsy and approximately 6 times the risk of decompensated liver disease (severe liver 
disease accompanied by clinical conditions including ascites, varices, or encephalopathy) 
when compared with HCV mono-infected patients. (15) Another meta-analysis of 27 
natural history studies found a relative risk (RR) of 1.72 of cirrhosis among patients 
coinfected with HIV/HCV compared to HCV mono-infected patients. (15, 16) An 
unusually rapid progression to cirrhosis was also demonstrated in a multicenter cross-
sectional study, where mean interval from estimated time of HCV infection to cirrhosis 
was significantly longer in HIV-negative than HIV-positive patients (23.2 vs 6.9 years, 
p<0.001). (17)  
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Accelerated fibrosis progression in the co-infected population has also been 
validated in multiple studies. In 282 HIV/HCV co-infected patients with 435 paired liver 
biopsies, fibrosis progression by at least 1 METAVIR stage after 2.5 years of follow-up 
was seen in 34% of the study population. (18) Two studies have demonstrated that while 
the majority of HIV/HCV co-infected patients did not show evidence of histologic 
progression over the course of 3 years, progression did occur in 16-24%. In a study of 
174 co-infected patients, significant fibrosis defined as two Ishak units or greater between 
biopsies occurred in 24% over a 3-year interval. (19) In another study, which was a 
retrospective review of 135 co-infected individuals with a median time of 3.3 years (2.0-
5.2) between repeat biopsies, 44% demonstrated fibrosis progression, with 16% having a 
2+ METAVIR stage increase. (14, 19)  
Mechanisms of Fibrogenesis in HIV/HCV Co-infection 
Liver fibrosis occurs when extracellular matrix (ECM) deposition exceeds the rate 
of ECM clearance and produces a net increase of ECM proteins that initiate the cascade 
of nodule development and cirrhosis. Hepatic stellate cells (HSC) have been implicated 
as the primary instigators of fibrogenesis and when activated by hepatocytes or Kupffer 
cells, HSCs become myofibroblast-like cells that produce ECM and tissue inhibitors of 
metalloproteinases (TIMPs) which further downregulate matrix degradation. (9)  
The mechanisms associated with accelerated fibrosis progression rates (FPR) 
among HIV/HCV co-infected patients may include direct viral effect on the hepatocytes 
and/or stellate cells, as direct activation of HSCs via HIV gp120 leads to increased 
expression and secretion of monocyte chemoattractant protein (MCP-1), a 
proinflammatory cytokine and stimulant of Type 1 collagen production. (20)  
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Additional mechanisms include diminished HCV-specific T cell responses, 
altered levels of matrix metalloproteinases and fibrosis biomarkers, increased oxidative 
stress and induction of hepatocyte apoptosis via CXCR4, HIV-associated gut depletion of 
CD4 cells, and immune/cytokine dysregulation. (21, 22) Markers of microbial 
translocation such as lipopolysaccharide, lipopolysaccharide binding protein, CD14, and 
fucose-binding lectin are raised in co-infected individuals and show strong correlation 
with HIV-related depletion of CD4+ cells and progressive HCV-related liver disease. 
(23) The reduced ratio of CD4+ to CD8+ cells associated with HIV infection may also 
play a role because CD8+ cells are more fibrogenic than CD4+ cells. (24) HIV/HCV co-
infected patients have increased intrahepatic IFN-gamma and TNF-alpha levels with 
higher IFN-gamma mRNA levels, which correlate with higher levels of fibrosis. (25) 
Moreover, HIV has been shown to accentuate an HCV-driven pro-fibrogenic program in 
hepatocyte and HSC lines through reactive oxygen species (ROS), NFkB, and TGFB1 
upregulation. (26)  
Increased risk of decompensation, mortality, and HCC 
Several studies have demonstrated an association between HIV/HCV coinfection 
and elevated rates of hepatic decompensation and mortality. One meta-analysis found an 
adjusted RR of 6.14 for decompensated cirrhosis, and similar increases in RR were found 
in a recent study where the incidence of decompensated cirrhosis was 7.4% compared to 
4.8% (p<.001) at 10 years in HIV/HCV co-infected compared to HIV mono-infected 
patients. (27, 28) There is also a significant increase in the risk of liver-related and all-
cause mortality in the co-infected population. In one study, mortality rates were higher in 
HIV/HCV co-infected patients with 1-year, 2-year, and 5-year survival estimates of 54, 
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40, and 25%, respectively, compared with 74, 61, and 44% in HCV mono-infected 
patients, highlighting that co-infection reduces the survival of patients with HCV-related 
end-stage liver disease and should be taken into consideration when establishing 
appropriate timing of liver transplantation. (29) The prevalence of HCC is also increased 
in HIV/HCV co-infection compared to HCV mono-infection, and HCC is estimated to 
occur after an average of 17.8 years compared with 28.1 years in HCV mono-infection. 
(30, 31)  
Factors affecting Fibrosis Progression 
Recent studies have begun to examine the factors affecting fibrosis progression in 
the co-infected population. A multivariate analysis identified 4 independent predictors of 
progression to cirrhosis in HIV/HCV co-infected patients: absence of PI therapy, heavy 
alcohol consumption, low CD4 count, and age at HCV acquisition. (32) Poorly controlled 
HIV mono-infection has also been found to be an independent risk factor for liver 
fibrosis. (10, 33) Another study found that fibrosis progression correlated with HIV RNA 
levels in a HIV/HCV co-infected population, further supporting the direct role of HIV in 
liver fibrogenesis. (34)  
Co-infected patients with undetectable HIV RNA through ART, in one study, had 
a slower fibrosis progression rate (FPR) than those with any detectable HIV RNA level 
and a FPR similar to HCV mono-infected patients, suggesting that HIV viremia and not 
CD4 cell count independently predicted FPR. (35) However, not all studies have 
supported a definitive role of poorly controlled HIV as indicated by viral load and CD4 
count in fibrosis progression. In a prospective cohort of 184 HIV/HCV co-infected 
individuals in which 24% demonstrated significant fibrosis progression over 3 years by 
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liver biopsy, measures of HIV disease and its treatment (CD4 cell count, HIV-RNA level, 
and ART exposure) were not significantly different compared to non-progressors. (19) 
After multivariate adjustment, only the serum AST level between biopsies was 
significantly associated with fibrosis progression, while covariates such as age, sex, race, 
HCV-RNA level, HCV genotype, ART, HCV therapy, CD4 cell count, and HIV-RNA 
level were not significantly associated with fibrosis progression.  
The accelerated fibrogenesis seen in HIV/HCV co-infection may be partially 
mitigated by ART. In an analysis of 2646 co-infected patients, the relative risk for 
cirrhosis for those not receiving ART was 2.49 (95% CI, 1.81-3.42), compared to 1.72 
(95% CI, 1.06-2.80) for those receiving ART, suggesting a protective but incomplete 
effect of ART on HCV-associated liver disease. (15) Another study found similar 
progression on liver histology between co-infected and HCV mono-infected patients 
where most patients were on effective ART, suggesting the benefits of ART on 
progression of HCV. (36) It is possible that HIV virologic suppression through ART 
lessens fibrogenic pathways through reductions in CD8+ T-cell activation. (37) 
Spontaneous clearance of HCV infection has been described occasionally in co-
infected patients with the IL28B CC genotype after initiating antiretroviral therapy and 
regaining immune competence. (13) Antiretroviral therapy interruption has also been 
found to be associated with increased risk of liver fibrosis progression in HIV/HCV co-
infected patients, with a hazard ratio for ART interruption of 2.52 (95% Confidence 
Interval [CI] 1.20-5.28). (38)  
The type of antiretroviral therapy may also play a role in modulating fibrogenesis. 
Recent studies have reported conflicting findings about the impact of protease inhibitor 
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(PI)- based therapy on fibrosis progression—one study reported that the use of PI-based 
ART in HIV/HCV co-infected patients was associated with less severe fibrosis and 
slower fibrosis progression, while another study found that the use of protease inhibitors, 
mainly lopinavir, was associated with increased liver fibrosis progression. (39, 40) 
Fibrosis progression in co-infected persons may be influenced to a greater degree by the 
antiretroviral therapy backbone more so than the class of anchor agent, as both PI- and 
NNRTI-based regimens were associated with increases in APRI score, another measure 
of hepatic fibrosis, over time when combined with abacavir/lamivudine (ABC/3TC). (41)  
The presence of metabolic derangements such as obesity, diabetes, and 
hyperlipidemia may also accelerate the progression to advanced fibrosis in the co-
infected population by generating a proinflammatory and high oxidative stress 
environment. Steatosis is a frequent histologic finding among patients with chronic 
Hepatitis C infection, and is significantly associated with body mass index as well as 
fibrosis. Thus, increasing body mass index (BMI) may play a role in the pathogenesis of 
steatosis in chronic Hepatitis C infection, and steatosis may contribute to fibrosis. (42) 
Insulin resistance and type 2 diabetes are also tightly linked to severe fibrosis, likely due 
to the ability of insulin to stimulate hepatic stellate cells and induce tumor necrosis-factor 
alpha and connective growth factor production. (43, 44) Moreover, hyperglycemia leads 
to enhanced formation and deposition of advanced glycation products that activate 
hepatic stellate cells, which may induce liver collagen production and upregulation of 
pro-fibrogenic cytokines. (44) In a cohort of patients with genotype 1 chronic HCV 
infection, not only was the presence of insulin resistance linked to advanced fibrosis, but 
overt type 2 diabetes also further increased the risk of severe fibrosis. (45) Diabetes has 
10 
 
been associated with a 2-3 fold increase in the risk of HCC, regardless of the presence of 
HCV, HBV, alcoholic liver disease, or non-specific cirrhosis. (46) Dyslipidemia may also 
be an important risk factor, as low HDL and diabetes were significantly associated with 
development of cirrhosis in a cohort of co-infected veterans. (47) 
A growing body of evidence suggests that the concurrent use of statins, 3-
hydroxy-3-methylglutaryl coenzyme A (HMG-coA) reductase inhibitors, in HIV/HCV 
co-infected patients may slow fibrosis progression due to their anti-inflammatory, 
immunomodulatory, and antineoplastic properties. In animal models, statins have 
demonstrated antifibrogenic effects by blocking the activation of hepatic myofibroblasts 
and preventing proliferation of hepatic stellate cells and collagen production. (48) Recent 
studies have reported an association between statin use and reduced risk of cirrhosis and 
HCC in the HCV mono-infected population. (48-50) In a large cohort of HIV/HCV co-
infected veterans, statin use >= 30% time was significantly associated with reduced risk 
of development of cirrhosis compared with those with less time on statin drugs. (47) 
Therefore, the benefits of statin use may extend beyond its cardioprotective properties to 
include reduction in cirrhosis progression in patients with chronic liver disease.  
Prior treatment with interferon-based therapy may also play a role in fibrosis 
progression. The antifibrotic effects of interferon α may be due to repression of the 
collagen gene (COL1A2) promoter sequence and collagen gene transcription. (51) A 
study of 74 co-infected patients found that those that received Pegylated-Interferon α-2a 
based therapy demonstrated significant decreases in fibrosis progression rate (FPR) and 
stabilization or regression of cirrhosis compared to those who received no treatment or 
interferon-based therapy. (52) Moreover, Peg-IFN α-2a/RBV therapy improved hepatic 
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histology and led to a decrease in fibrosis progression not only in patients who achieved 
sustained virologic response (SVR) but also in non-responders, suggesting that the 
benefits of treatment with Peg-IFN α-2a/RBV may extend beyond viral clearance to 
histologic improvement and delayed fibrosis progression.  
The order of acquisition of HIV and HCV may be an important consideration. 
Historically, most co-infected patients acquired HCV first through parenteral routes and 
then subsequently became infected with HIV. This order of infection is the rule in 
patients with parenteral exposures because HCV is much more infectious than HIV via 
parenteral routes. (53) However, this paradigm has shifted in recent years with an 
emerging epidemic of sexually acquired HCV infection among HIV-infected men who 
have sex with men (MSM), where the order of infection is reversed because HIV is more 
infectious than HCV through sexual transmission. (54) Available evidence shows that 
these HIV-infected men rapidly progress to moderate levels of fibrosis within the first 
year of HCV infection, and some with the most severe immunocompromise experience 
further rapid progression to cirrhosis. (55) Additional prospective studies are necessary to 
more clearly define the long-term outcomes of these HIV-infected men after HCV 
infection. 
Methods for Assessing Fibrosis Progression 
The accurate evaluation of severity of liver fibrosis in chronic hepatitis C is 
critical for determining therapeutic indications and prognosis. Among the available 
methods for assessing liver fibrosis, liver biopsy is currently considered the gold standard 
but its use is limited by cost, invasiveness, and potential complications such as pain, 
bleeding, peritonitis, and bowel perforation. Due to limited sampling of the liver 
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parenchyma, liver biopsy is demonstrated to carry a diagnostic error rate of 20% for 
fibrosis stage. (56) Increasingly, non-invasive tools such as serologic-based scores are 
being utilized, including the AST-to-platelet ratio (APRI), FIB-4, FibroTest, FibroSpect 
II, HepaScore, as well as imaging-based methods such as vibration controlled liver 
elastography. However, routine use of many of these noninvasive tests can still be 
hampered by cost, false negative or positive results, or the need for standardization 
assays.  
FIB-4, the assessment tool used in this study, is a simple index which was 
specifically developed in 832 co-infected patients enrolled in the AIDS Pegasys Ribavirin 
International Coinfection Trial (APRICOT). In many respects, the FIB-4 serves as a 
highly useful clinical tool—it is based on simple calculations and easy to use, results are 
available in a timely fashion, and it is inexpensive, relying only on readily available clinic 
parameters such as age, ALT, AST, and platelet count without additional costs for 
equipment. FIB-4 <1.45 was associated with a sensitivity of 70% and a NPV of 90% to 
exclude advanced fibrosis, while a score >3.25 had a specificity of 97%, and a PPV of 
65%. Values between 1.45 to 3.25 were classified as indeterminate. (57)  
Since the APRICOT trial, FIB-4 has subsequently been validated in multiple 
studies as a simple, accurate, and inexpensive method for assessing liver fibrosis for 
values outside 1.45-3.25, and shows promise for application in emerging countries where 
more expensive and invasive methods of assessing fibrosis are not accessible. (58-60) 
Moreover, it is not only predictive of advanced fibrosis, but also of liver-related clinical 
outcomes and overall mortality. (61, 62) 
Treatment of HIV/HCV Co-Infection 
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 For many years, the standard therapy for treatment of chronic hepatitis C has been 
pegylated interferon α (Peg-IFN) and ribavirin (RBV), administered for 24- to 48-weeks 
depending on the genotype. Under this regimen, viral eradication rates were suboptimal. 
In patients with genotype 1 HCV, sustained virologic response (SVR) rates were 40% 
following 48 weeks of Peg-IFN/RBV and even lower in those with African descent, HIV 
co-infection, or high viral loads or advanced fibrosis. (63-65) In addition, significant side 
effects associated with interferon and ribavirin therapy have also hindered patient 
tolerance. Interferon treatment is associated with myelosuppression, flu-like symptoms, 
neuropsychiatric symptoms, and also lowers the seizure threshold and exacerbates 
immune-mediated conditions. (66) The addition of ribavirin confers additional risks of 
hemolytic anemia, rash, and insomnia.  
However, the advent of revolutionary new interferon-free direct-acting antiviral 
agents (DAA) has radically changed the face of HCV therapy. DAAs are designed to 
inhibit viral proteins involved in the HCV life cycle, with numerous potential targets such 
as the NS3/4A serine protease, NS5A replication complex protein, NS5B RNA-
dependent RNA polymerase, and NS4B and NS3 helicase proteins. (67) With the 
proliferation of DAAs that offer the potential of highly effective and well-tolerated 
treatment, regimen selection varies depending on patient genotype and factors such as the 
presence of cirrhosis and prior treatment history.  
 In contrast to the previous paradigm in the interferon era, the DAA era has seen 
comparable HCV cure rates of over 90% in HIV/HCV co-infected patients, eliminating 
the need for distinguishing between mono- and co-infected patients. (68) The efficacy of 
DAAs was first demonstrated in trials of the protease inhibitors telaprevir and boceprevir 
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added to peginterferon and ribavirin, and further confirmed in trials of the newer DAAs, 
even with regimens that do not contain interferon. It is notable, however, that most 
clinical trial data on the efficacy of HCV therapy derives from patients on antiretroviral 
therapy with suppressed HIV viral loads and CD4 counts greater than 200 cells/mm3 and 
may lack generalizability in the real world. (69-74) Thus, curative all-oral treatment is a 
possibility for all HIV/HCV co-infected patients.  
A major consideration is monitoring drug-drug interactions between antiretroviral 
therapy and DAAs. For example, because ledipasvir (an NS5a inhibitor) and sofosbuvir 
(an NS5b inhibitor) are both substrates of the P-glycoprotein transporter, concomitant use 
of ritonavir boosted tipranavir is not recommended because it may decrease levels due to 
induction of the transporter. Simeprevir (HCV protease inhibitor) is oxidatively 
metabolized by the CYP3A subfamily and not recommended for use with HIV protease 
inhibitors boosted by ritonavir. (75)  
Theoretically, all patients with virologic evidence of chronic HCV infection 
should be considered for treatment; however, there are clinical characteristics that are 
taken into account when deciding when to initiate HCV therapy. Per the American 
Association of the Study of Liver Diseases (AASLD) and Infectious Disease Society of 
America (IDSA) guidelines, treatment should not be withheld from those who currently 
use illicit drugs or those who are in an opioid treatment program, provided that they wish 
to be treated, are willing and able to maintain close monitoring, and practice 
contraception; however, many healthcare providers remain reluctant to treat this at-risk 
population. (76) Although history of alcohol abuse is not an absolute contraindication to 
treatment, continued alcohol use has been shown to decrease the response to interferon-
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based therapy and accelerate disease progression. (77, 78) Limited data is available on 
the effectiveness of DAAs in patients who continue to drink.  
Financial constraints continue to prevent the widespread availability of novel 
DAA regimens. Sofosbuvir is an example of a new oral HCV medication that, when 
combined with other therapies, has a therapeutic efficacy (cure) greater than 90% across 
4 genotypes, limited adverse effects, and a shorter treatment window than its interferon-
based predecessors; however, its cost forces payers to ration this lifesaving treatment. 
One study in Massachusetts found that the mean drug cost per patient per SVR was 
$123,559 for ledipasvir/sofosbuvir and $251,550 for sofosbuvir + simeprevir. (79) It is 
estimated that third-party payers would need $136 billion to cover medication costs for 
all eligible patients with HCV from 2015-2020, of which $61 billion would need to be 
paid by the government. (80) For this reason, some payers restrict access only to patients 
in more advanced stages of disease, in some cases requiring fibrosis scores of F3 or F4 
before covering a DAA medication. (81) In addition, many prior authorization criteria 
require abstinence from the use of alcohol, illicit drugs, or both in the months leading up 
to treatment approval, presenting another barrier to treatment. The immense budgetary 
impact on private and government providers that would be incurred from treating all 
eligible patients with HCV in the United States continues to preclude widespread access 
to treatment, making knowledge of the factors that predict fibrosis progression in the 
HIV/HCV co-infected population all the more critical for effective resource allocation. 
Current guidelines suggest a high priority for treating the HIV/HCV co-infected 
population given the more rapid progression to advanced liver disease in the setting of 
HIV infection. (82) Achieving SVR has been associated with improved overall survival 
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in co-infected patients even in lower stages of fibrosis (F0-F2), suggesting that HCV 
therapy may provide benefits beyond the cure of HCV and may prevent the progression 
of liver disease. (83) However, it seems reasonable to adopt a “wait and see” policy for 
patients with little or no fibrosis (F0-F1) since they are unlikely to progress while taking 
stable cART, while for patients with advanced fibrosis, treatment should be prioritized 
because fibrosis has already developed and cirrhosis may occur. (68) Therefore, 
determination of the presence of significant fibrosis or liver cirrhosis is vital for resource 
allocation and treatment prioritization purposes. As a corollary, predicting who is likely 
to progress would be important for resource allocation as well. Finally, longitudinal 
natural history studies in an established cohort are uncommon, but provide critical 




The purpose of this study is to elucidate the natural history and identify potential 
predictors of fibrosis progression in the HIV/HCV co-infected population. We 
hypothesized that in our co-infected cohort, elevated BMI, history of alcohol abuse, low 
CD4 count, and elevated HIV viral load would be associated with faster fibrosis 
progression. We analyzed data collected retrospectively and examined (a) patient 
demographics and clinical characteristics within this group of patients; (b), the non-
invasive score FIB-4 in order to describe patterns of fibrosis progression over 5 years; 
and (c), the association of various factors such as BMI, diabetes, hyperlipidemia, history 





Study subjects were selected from HIV/HCV co-infected patients receiving care 
at the Nathan Smith Clinic of Yale-New Haven Hospital from June 2002 through April 
2016. The date of study entry was the date of last laboratory values prior to treatment 
with DAAs or the most recent laboratory values for patients not treated with DAAs. Data 
going back 5 years was chosen because a 5-year time interval has been postulated as the 
average time to progression between stages of liver fibrosis. Patients who did not have 
cirrhosis (as defined by FIB-4>3.25) at 5 years prior to study entry were eligible for the 
study.  
On a retrospective review of medical records, data on the following variables 
were collected: demographics such as gender and race, clinical characteristics related to 
HCV and HIV such as year of HIV and HCV diagnosis as recorded in chart notes (if 
known), mode of HCV acquisition, HCV genotype, antiretroviral therapy type and 
backbone, prior treatment for HCV with interferon-based therapy, liver biopsy stage if 
performed, and DAA treatment course if treated. The body mass index (BMI) used in the 
analysis was the value recorded closest to the date of study entry. Diagnosis of diabetes 
was based on the presence of diabetes mellitus on the patient’s problem list, or at least 2 
Hemoglobin A1c values ≥ 6.5. Diagnosis of hyperlipidemia was captured as charted in 
patients’ medical record, or at least 2 values of elevated total cholesterol over the 
previous 5 years. Statin use was recorded if a statin was on the patient’s medication list at 
the time of study entry. History of smoking was positive if the patient was a current or 
former smoker as recorded in clinic notes at the time of study entry. The Alcohol Use 
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Disorders Identification Test (AUDIT)- C score was recorded as the highest AUDIT-C 
score recorded at a patient visit during the 5 years prior to study entry; the AUDIT-C 
score is routinely calculated at each clinic visit, with scores of 4 or more in men and 3 or 
more in women considered a positive screen and optimal for identifying hazardous 
drinking or active alcohol use disorders. History of alcohol abuse was determined by any 
prior history of alcohol abuse recorded in visit notes. Active drug use was determined as 
documented in visit notes or positive urine toxicology screen for cocaine or opiates 
within the previous 6 months before study entry. Hepatitis B co-infection was indicated 
by positive Hepatitis B surface antigen (HBsAg). The VACS score (Veterans Aging 
Cohort Study) at time of study entry was calculated using the patient’s age, sex, race, 
CD4 count, HIV viral load, hemoglobin, AST, ALT, platelet count, FIB-4, Creatinine, 
eGFR, and Hepatitis C status at the time of study entry, using the calculator provided at 
https://vacs.med.yale.edu/calculator/IC. VACS scores typically range from 0 to 100, with 
a higher score indicating worse prognosis and increased risk of mortality. 
Routine laboratory values including AST, ALT and platelet count were extracted 
to calculate the FIB-4 score, which is computed as follows: FIB-4 = age [years] × AST 
[IU/L]/platelet count [platelets ×109/L] × (ALT1/2[IU/L]). Yearly FIB-4 scores dating 
back 5 years were calculated from the last FIB-4 prior to treatment initiation for patients 
treated with DAAs, or the most recent FIB-4 for patients not treated with DAAs. The 
mean of 3 values closest to the chosen time point was used to calculate the annual FIB-4 
score. The closest CD4 count, CD4/CD8 ratio, HIV viral load, and HCV viral load 
obtained within 6 months of the annual FIB-4 score was recorded. In order to obtain 3 
year and 5 year log viral loads and CD4 counts, all log viral loads or CD4 counts for each 
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patient over the 3 year or 5 year period prior to study entry were extracted and the mean 
of all the available values was obtained.  
The primary outcome measure of the study was progression to advanced fibrosis, 
indicated by FIB-4 levels exceeding the value of 3.25, and patients were categorized 
based on FIB-4 progression over the course of 5 years. Progressors were defined as those 
whose FIB-4 progressed from below 3.25 to above 3.25 while non-progressors were 
defined as those whose FIB-4 remained below 3.25. Descriptive statistics were used to 
assess baseline characteristics. In order to compare progressors vs non-progressors, 
parametric (t-tests) or non-parametric (Wilcoxon scores) methods were used for 
continuous variables as appropriate; Chi-square or Fisher’s exact test were used for 
categorical variables as appropriate. Univariate logistic regression models were used to 
examine factors associated with progression to FIB-4 >3.25: such models were used for 
age, BMI, diabetes, hyperlipidemia, statin use, alcohol abuse, injection drug use, HIV 
viral load, CD4+ cell count, among others. Variables were chosen for inclusion in a 
multivariable model based on a univariate model p-value of ≤ 0.20. A p value less than 
0.05 was considered statistically significant. Statistical analysis was performed using 
SAS v9.4 (SAS Institute Inc., Cary, NC). The Yale University Institutional Review Board 




Of 126 HIV/HCV co-infected patients, 93 started out with initial FIB-4 scores 
below 3.25, indicating lack of advanced fibrosis. This subgroup of 65 males and 28 
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females had mean age of 56.7 years and average BMI of 27.1; 32.3% were white, 53.8% 
were black, 11.8% identified as Hispanic (Table 1). 15.0% of patients had diabetes, 
22.6% had a history of hypercholesterolemia, and 17.2% were prescribed a statin. 90.3% 
were current or former smokers, and 25% demonstrated active drug use. 50.5% of 
patients had documented history of alcohol abuse within the chart. The mean AUDIT-C 
score was 1.1 and 56.0% had an AUDIT-C score of 0. The mean VACS score was 38.5, 
corresponding to a 5-year mortality rate of approximately 18%, and only 2 patients were 
also co-infected with hepatitis B.  
Table 1. Baseline characteristics of 93 HIV/HCV co-infected patients 
Characteristic Total (N=93) 
Age, mean years 56.7 
Gender 
     Male 






     White 
     Black 
     Hispanic 






Body mass index, mean kg/m2 27.1 
History of diabetes 14 (15.1%) 
History of hyperlipidemia 21 (22.6%) 
Statin use 16 (17.2%) 
Ever smoker 84 (90.3%) 
History of alcohol abuse 46 (49.5%) 
Active drug use 23 (25.0%) 
AUDIT-C Score (highest recorded) 
     0-3 






VACS Index Score, mean (range)1 38.5 (5-107) 
Hepatitis B co-infection 2 (2.2%) 
AUDIT, Alcohol Use Disorders Identification Test; VACS, Veterans Aging Cohort Study 





Injection drug use was the predominant risk factor for HCV acquisition (63.4%), 
followed by both injection drug use and heterosexual transmission (12.9%), heterosexual 
transmission alone (6.5%), and men who have sex with men (MSM) (3.2%) (Table 2). 
The duration of HCV infection was available for 27 patients and the mean was 19.8 
years. Genotypes included: genotype 1 (81.2%), genotype 3 (9.4%), genotype 2 (5.9%) 
and genotype 4 (3.5%). 15 patients (16.1%) had prior treatment with interferon-based 
therapy. Of 38 patients who had ever received a liver biopsy, 47.4% (18) showed no to 
mild fibrosis (F0-F1), 36.8% (14) showed moderate fibrosis (F2), 7.9% (3) showed 
severe fibrosis (F3), and 7.9% (3) showed evidence of cirrhosis (F4). Of the three patients 
with biopsy proven cirrhosis, FIB-4 showed concordance with liver biopsy in two 
patients.  
52 patients were subsequently treated with DAAs while 41 remained untreated at 
the time of data collection. Of those treated with DAAs, the majority (65.4%) were 
treated with ledipasvir/sofosbuvir, 15.4% were treated with sofosbuvir/ribavirin, 9.6% 
with sofosbuvir/simeprevir, 7.7% with sofosbuvir/daclatasvir, and 1.9% with other 
regimens.  
 
Table 2. HCV-Specific Characteristics 
HCV-Specific Characteristic Total (N=93) 
Risk mode of HCV acquisition 
     IDU alone 
     IDU and heterosexual 
     Heterosexual 
     MSM 
     Blood Transfusion 










     tattoos, blood transfusion 
     Unknown 
 
12 (12.9%) 
Duration of HCV infection, mean years1 19.8 
HCV Genotype 
     1 
     2 
     3 






Liver biopsy performed 
     F0-1 
     F2 
     F3 






Subsequent treatment with DAA 
DAA treatment regimen: 
     Ledipasvir/sofosbuvir 
     Sofosbuvir/ribavirin 
     Sofosbuvir/simeprevir 
     Sofosbuvir/daclatasvir 








1.Data on year of HCV diagnosis available in 27 patients 
 
HIV-Specific Characteristics 
The mean duration of HIV infection based on year of HIV diagnosis was 
available for 82 patients and was 22.3 years (Table 3). At the time of study entry, the 
median CD4 count was 564 cells/mm3 (Interquartile Range [IQR] 368, 891) the median 
CD4/CD8 ratio was 0.7 (IQR 0.4, 1.1), and the median historical nadir CD4 count was 
308 cells/mm3 (IQR 186, 498). The majority (88.4%) had HIV viral loads <500 
copies/mL. 
The vast majority of patients (97.9%) were on antiretroviral therapy; 29% were on 
a protease inhibitor-based regimen, 28.0% were on a non-nucleoside reverse transcriptase 
inhibitor (NNRTI)- based regimen, and 28.0% were on an integrase strand transfer 
inhibitor (INSTI)-based regimen. The antiretroviral regimen backbone consisted of 
tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for 67.7%, and 




Table 3. HIV-Specific Characteristics 
HIV-Specific Characteristic Total (N=93) 
Duration of HIV infection, mean years 22.3 
CD4+ Cell count, median (IQR) 564 (368, 891) 
CD4/CD8 ratio, median (IQR) 0.7 (0.4, 1.1) 
Nadir CD4+ count, median (IQR) 308 (186, 498) 
HIV-1 RNA <500 copies/mL at study entry  
n (%) 
76 (88.4%) 
On ART n (%) 
ART treatment regimen (n): 
     PI-based 
     NNRTI-based 
     INSTI-based 
     (INSTI and PI) NRTI sparing 
     Other1 
ART backbone (n): 
     TDF/FTC 
     ABC/3TC 












1. Other regimens included: raltegravir(RAL)/tenofovir disoproxil 
fumarate(TDF)/emtricitabine(FTC)/darunavir(DRV)/ritonavir(r) (3), 
TDF/FTC/DRV/r/DTG(dolutegravir), RAL/3TC/ATZ(atazanavir)/r, RAL/TDF/FTC/ATZ/r, 
RPV(rilpivirine)/TDF/FTC/DRV/c(cobicistat), RAL/TDF/FTC/ETR(etravirine)/DRV/r 
 
Progression to Advanced Fibrosis 
Over the course of 5 years, 68 patients (73.1%) had FIB-4 remain below 3.25, 
while 25 (26.9%) had FIB-4 progress to >3.25 (Table 4, Figure 1). Of the 68 non-
progressors, 23 patients started out below 1.45, and 14 remained below 1.45 after 5 years. 
Five years prior to study entry, the annual mean FIB-4 score of the full cohort started at 
1.93, trending upward to 2.07 at 4 years, 2.25 at 3 years, 2.37 at 2 years, 2.46 at 1 year, 
and 2.44 at the time of study entry. In patients whose FIB-4 remained below 3.25 (non-
progressors), the mean annual FIB-4 scores from 5 years to time of study entry were 1.73, 
1.81, 1.82, 1.88, 1.91, and 1.73. In patients whose FIB-4 progressed to above 3.25 
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(progressors), the mean annual FIB-4 scores from 5 years to time of study entry were 
2.49, 2.91, 3.31, 3.77, 3.88 and 4.37. The difference between lowest and highest FIB-4 
scores was 1.39 in progressors and 0.18 in non-progressors.   
 






t = -5 
Mean 
(SD) FIB-
4 4 years 




t = -3 
Mean 
(SD) FIB-
4 2 years 





t = -1 
Mean FIB-4 
(SD) at time 
0 





2.49 (0.51) 2.91 
(1.00) 









1.73 (0.63) 1.81 
(0.84) 






















Mean FIB-4 of all patients
Mean FIB-4 of Progressors





Comparison of Progressors to Non-Progressors 
We hypothesized that markers of HIV and HCV disease severity such as duration 
of disease and quantitative markers would differ between progressors and non-
progressors. Duration of HIV and HCV infection (when available), mean HIV and HCV 
viral load, nadir CD4 count, CD4 count, and CD4/8 ratio (over the 3 or 5 years prior to 
study entry) did not differ significantly between patients who progressed to >3.25 and 
patients who remained <3.25 (Table 5).   
 
Table 5. Correlates of Fibrosis Progression 
Characteristic Non-progressors (N = 68) 
Mean +/- S.D. 
Progressors (N = 25) 
Mean +/- S.D. 
P value1 
HCV duration, years 
(*N=27) 
20.0 +/- 8.9 19.0 +/-12.5 0.95 
HIV duration, years (N = 
82) 
22.6 +/- 6.6 21.4 +/- 8.4 0.51 
Mean log HCV viral load 
(from t= 0 to t=-3) 
6.3 +/- 1.1 5.7 +/- 1.0 0.02 
Mean log HCV viral load 
(from t=0 to t=-5) 
6.3 +/- 1.1 5.9 +/- 1.1 0.08 
Mean log HIV viral load 
(from t=0 to t=-3) 
2.0 +/- 0.7 2.2 +/- 0.9 0.14 
Mean log HIV viral load 
(from t=0 to t=-5) 
2.0 +/- 0.6 2.2 +/- 0.8 0.21 
Mean CD4 count (from t=0 
to t=-3) 
633 +/- 342 551 +/-336 0.31 
Mean CD4 count (from t=0 
to t=-5) 
618 +/- 336 550 +/- 323 0.38 
Mean CD4/CD8 ratio 
(from t=0 to t=-3) 
0.7 +/- 0.5 0.9 +/-0.7 0.22 
Mean CD4/CD8 ratio 
(from t=0 to t=-5) 
0.7 +/- 0.4 0.9 +/- 0.7 0.13 





Predictors of Fibrosis Progression 
In univariate logistic regression models, age, gender, race, BMI, alcohol abuse, 
active injection drug use, diabetes, hyperlipidemia, statin use, HIV and HCV duration and 
viral load, and CD4 count did not significantly predict progression to advanced fibrosis 
(Table 6). A number of variables were suggestive of a protective trend (such as 
hyperlipidemia, statin use, AUDIT score <4, HIV viral load <500 copies/mL), however, 
they did not achieve statistical significance. Similarly, the use of non-NNRTI-based 
regimen appeared protective but was not statistically significant. The 3 year mean log 
HCV viral load (defined as the mean log HCV viral load in the 3 years prior to study 
entry for whom data was available) showed a statistically significant effect favoring low 
HCV viral loads predictive of fibrosis progression. Conversely, a CD4 count <100 
cells/mL at the time of study entry appeared to correlate with higher risk of progression, 
but this was not statistically significant.  
In a multivariable logistic regression model, age, race, gender, CD4 count, viral 
load, hemoglobin, and estimated glomerular filtration rate (eGFR) were not found to be 
significant, in addition to AUDIT score, ART class or backbone, statin use, and 3 year 
mean HIV viral load (Table 7). 
 
Table 6. Univariate Analysis of Correlates of Fibrosis Progression 
Demographic characteristic Odds Ratio >1 (95% 
CI) 
‘Elevated’ Risk 
Odds Ratio <1 (95% 
CI) 
‘Reduced’ Risk 
Age 1.01 (0.94, 1.08)  
Female vs male 1.13 (0.42, 3.04)  
Black vs non-black  0.73 (0.29, 1.83) 
BMI <18.5 vs >=30 kg/m2 1.91 (0.26, 13.87)  
BMI 18.5-<25 vs >=30 kg/m2 1.43 (0.48, 4.24)  
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BMI 25-29 vs >=30 kg/m2  0.45 (0.10, 2.00) 
Comorbid conditions 
History of alcohol abuse  0.92 (0.37, 2.31) 
Active drug use  0.93 (0.32, 2.71) 
Diabetes 1.64 (0.49, 5.47)  
Hyperlipidemia  0.57 (0.17, 1.90) 
Statin use  0.34 (0.07, 1.60) 
Ever smoker  0.71 (0.16, 3.08) 
AUDIT score <4 vs 4+  0.59 (0.12, 2.93) 
HIV-specific characteristic 
PI-based ART 1.21 (0.45, 3.28)  
Non-NNRTI based ART  0.56 (0.19, 1.69) 
ABC/3TC ART 1.34 (0.45, 4.01)  
HIV duration in years  0.98 (0.91, 1.05) 
HIV viral load <500 vs >=100,000 
copies/mL at study entry 
 0.36 (0.05, 2.71) 
HIV viral load 500-9999 vs 
>=100,000 copies/mL at study 
entry 
 0.50 (0.02, 11.09) 
3-year mean log HIV viral load 1.52 (0.86, 2.68)  
5-year mean log HIV viral load 1.48 (0.79, 2.79)  
CD4 count <100 vs >=500 cells/mL 
at study entry 
6.91 (0.57, 83.5)  
CD4 count 100-199 vs >=500 
cells/mL at study entry 
3.46 (0.61, 19.59)  
CD4 count 200-349 vs >=500 
cells/mL at study entry 
1.48 (0.33, 6.70)  
CD4 count 350-500 vs >=500 
cells/mL at study entry 
1.15 (0.34, 3.88)  
3-year mean CD4/CD8 ratio 1.66 (0.73, 3.76)  
5-year mean CD4/CD8 ratio 1.96 (0.81, 4.76)  
HCV-specific characteristic 
HCV duration in years  0.99 (0.89, 1.10) 
HCV duration, <10 vs 10+ years  0.15 (0.02, 1.50) 
3-year mean log HCV viral load  0.62 (0.38, 1.00) 
5-year mean log HCV viral load  0.70 (0.46, 1.08) 
Prior HCV treatment 1.45 (0.44, 4.76)  
For continuous variables, the odds ratio refers to the per unit increase in risk.  
 
Table 7. Multivariate Analysis of Correlates of Fibrosis Progression 
Demographic Characteristic Odds Ratio (95% CI) 
Age 0.99 (0.90, 1.09) 
Female sex 0.80 (0.20, 3.13) 
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Black race 1.03 (0.28, 3.72) 
Comorbid conditions 
AUDIT-C score level 0.53 (0.10, 2.71) 
Statin use 0.40 (0.08, 1.96) 
Hemoglobin <10 vs >=14 g/dL 1.85 (0.04, 87.17) 
Hemoglobin 10-11.9 vs >14 g/dL 1.14 (0.19, 6.80) 
Hemoglobin 12-13.9 vs >=14 g/dL 3.11 (0.89, 10.82) 
eGFR <30 vs >=60 mL/min 1.47 (0.07, 31.61) 
eGFR 30-44.9 vs >=60 mL/min  6.40 (0.65, 63.49) 
eGFR 45-59.9 vs >=60 mL/min 3.71 (0.69, 19.90) 
HIV-specific characteristics 
CD4 count <100 vs >=500 cells/mL at study entry 19.01 (0.28, 1000) 
CD4 count 100-199 vs >=500 cells/mL at study entry 12.13 (0.67, 221.30) 
CD4 count 200-349 vs >=500 cells/mL at study entry 1.40 (0.22, 8.86) 
CD4 count 350-500 vs >=500 cells/mL at study entry 0.92 (0.21, 3.99) 
Log HIV viral load at study entry 0.72 (0.29, 1.82) 
3-year mean log HIV viral load 1.50 (0.85, 2.66) 
PI-based ART 1.01 (0.34, 3.01) 
Non-NNRTI based ART 0.52 (0.15, 1.82) 
ABC/3TC ART 0.98 (0.30, 3.23) 
HCV-specific characteristics 
Prior HCV treatment with interferon 1.67 (0.49, 5.71) 
 
Discussion: 
Patients with chronic hepatitis C and HIV co-infection exhibit more rapid 
progression to advanced liver disease, making coinfection a compelling reason to 
prioritize a patient for HCV antiviral therapy, particularly in the era of highly effective 
and well-tolerated DAAs. However, in the current era, DAAs are not widely accessible 
for those in need due to prohibitive costs and resource constraints, making the 
prioritization of patients at greatest risk of fibrosis progression an important 
consideration.  
In this study of 93 HIV/HCV co-infected patients without baseline advanced 
fibrosis based on FIB-4, we found that 26.9% progressed to advanced fibrosis over 5 
years of follow-up. This observed incidence of fibrosis progression over a relatively short 
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interval is consistent with prior studies of HIV/HCV co-infected patients where 
progression to advanced fibrosis also occurred in as few as 3 to 5 years. (14, 18, 84) 
Fibrosis progression of two Ishak fibrosis stages has been observed in only 8-12% 
of HCV mono-infected patients over median intervals of 30-44 months, and a recent 
study of nearly 14,000 HIV-infected patients found that 10% of HIV mono-infected 
patients progressed to advanced fibrosis compared to 24% of HCV co-infected patients in 
a median of 3 years (p<0.01). (33, 85, 86) Since our patients had likely been infected with 
HCV for many years prior to the study period, our findings may also suggest that fibrosis 
progression in the co-infected population does not always follow a linear trajectory of 
inevitable progression, necessitating serial monitoring to facilitate detection of 
individuals with progressive disease prior to the onset of clinical liver disease. (18)  
 We did not find history of alcohol abuse, hyperlipidemia, diabetes, BMI, CD4 
count, and HIV viral load to be statistically significant predictors of fibrosis progression 
(Table 6), although there appeared to be an association between HIV viral load and CD4 
count at time of study entry and risk of fibrosis progression. There was a consistent trend 
towards increased risk of fibrosis progression with increasing viral load—HIV viral load 
<500 vs >=100,000 copies/mL showed OR 0.36, and the mean log HIV viral loads over 3 
years and 5 years showed OR of 1.52 and 1.48, respectively. The CD4 level at study 
entry also showed an increasing OR with each decreasing level, with OR of 1.15 for 350-
500 vs >=500 cells/mL, OR of 1.48 for 200-349 vs >=500 cells/mL, OR of 3.46 for 100-
199 vs >=500 cells/mL, and OR of 6.91 for <100 vs >500 cells/mL, although these 
differences did not achieve statistical significance. The evidence implicating these 
variables is conflicting in the literature. In a small study of 30 co-infected patients, heavy 
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alcohol consumption, metabolic disorder, CD4 count, and HIV viral load were not 
significantly associated with fibrosis progression, and only elevated ALT (p<0.001) and 
AST (p<.0340) higher than 3 times the upper limit of normal were associated with 
fibrosis progression. (87) This was consistent with the findings of another study of 174 
patients in which only the serum AST level was significantly associated with fibrosis 
progression while other covariates such as age, sex, race, CD4 cell count, and HIV-RNA 
did not show a significant association. (19)  
In contrast, other studies have reported an association between low CD4 count 
and fibrosis progression. (47, 88, 89) This was supported by increasing odds ratios for 
each decreasing level of CD4 count at time of study entry in Table 6. One could assert 
that the majority of our patients had clinically stable HIV infection with undetectable 
HIV viral loads due to ART, making it difficult to detect any association between CD4 
count and liver fibrosis progression.  
We also examined the CD4/CD8 ratio because the CD4/CD8 ratio is emerging as 
a biomarker of immune activation and systemic inflammation in HIV positive patients. 
Our data showed that increasing CD4/CD8 ratio may have been associated with increased 
risk of fibrosis progression, which was unexpected because chronic HCV infection has 
been associated with low CD4/CD8 ratios in HIV positive women in a recent study. (90) 
However, this same study observed low CD4/CD8 ratios in women with cleared HCV 
infection, highlighting that T-cell dynamics are not well elucidated in the HIV/HCV co-
infected population.   
In our study, age did not predict risk of fibrosis progression, although some 
studies have identified older age as an independent predictor of fibrosis progression. (91, 
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92) Black race did not confer a protective effect on the development of fibrosis in our 
patient population (p = 0.59), in contrast to previous findings that black race was 
associated with lower rates of hepatic decompensation. (28) Despite studies reporting 
improved liver histology and slower fibrosis progression rate among treated non-
responders compared to non-responders, we did not detect an effect of prior interferon-
based HCV treatment on fibrosis progression in our cohort, of which 16.1% had received 
prior treatment (p = 0.54). (52) AUDIT score less than 4 may have been protective (OR 
0.59), though this finding was not statistically significant (0.51).  
 Multiple studies have supported the lack of correlation between HCV viral load 
and fibrosis progression in the HCV mono-infected population (93-95)  In the setting of 
co-infection, HCV RNA levels increase after HIV seroconversion and continue to 
increase over time compared to patients with HCV alone. (53) The level of HCV viremia 
is inversely correlated with lower CD4 counts in most studies; however, overall increases 
in the HCV viral load do not appear associated with severity of liver disease. (96, 97) In 
our results, the 3 year mean log HCV viral load appeared to differ significantly between 
progressors and non-progressors (p = 0.02, Table 5), however statistical significance was 
not seen for the 5 year mean log HCV viral load (p = 0.08) and the univariate logistic 
regression model showed borderline significance (p = 0.05), suggesting that any 
difference in HCV viral load between progressors and non-progressors was either 
confounded by other parameters or was a random chance finding.  
Suppression of HIV infection through ART has been associated with slower liver 
fibrosis regression rate; however, there is conflicting data regarding the impact of type of 
ART on fibrosis progression. The use of protease inhibitors, mainly lopinavir, was 
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associated with increased liver fibrosis progression in one study, while another reported 
that PI-based ART was a protective factor against fibrosis progression. (39, 40) 
Moreover, a recent study asserts that the choice of antiretroviral backbone influences 
fibrosis progression more than the class of anchor agent, with abacavir/lamivudine 
containing regimens associated with fibrogenesis. (41) However, we failed to find a 
significant association between fibrosis progression and ART class (p = 0.70 for PI, 
p=0.30 for NNRTI) or ABC/3TC backbone (p = 0.61). This could be because in our 
cohort of primarily immunocompetent patients, the effect of ART on fibrogenesis may be 
subtle and require observation for a duration longer than a 5 year period.  
Statin therapy in HCV mono-infection has been shown to reduce cirrhosis risk by 
69-87%, and recently, has also been demonstrated to mitigate the risk of liver disease 
progression in HIV/HCV co-infected patients. (47, 48, 50) However, we did not find a 
statistically significant association between statin use and fibrosis progression (p = 0.17) 
although there seemed to be a protective trend (OR 0.34). This may be because in our 
study, only a few patients (17.2%) received statin prescriptions although 22.6% had a 
recorded history of hyperlipidemia. Thus, our ability to detect any protective effects 
associated with statin therapy is limited. Although there are safety concerns about the 
potential hepatotoxicity associated with statins, statin use in the presence of liver disease 
or enzyme elevation is generally safe and well tolerated. (98) Further prospective studies 
would be needed to better understand the efficacy of statin drugs as adjunct therapy in the 
care of HIV/HCV co-infected patients. It is worth noting that HIV-infected patients have 
a greater prevalence of dyslipidemia, earlier incidence and progression of atherosclerosis, 
and a nearly twofold increased risk for myocardial infection compared to those without 
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HIV, making a compelling case for increased statin use in the HIV-infected population 
for cardiovascular disease prevention. (99)  
We did not find a significant association between BMI, diabetes, and 
hyperlipidemia and risk of fibrosis progression, in contrast to previous studies which 
have identified that metabolic risk factors such as obesity, low HDL, and diabetes are 
associated with development of cirrhosis. (18, 33, 47) Conversely, we found that the 
diagnosis of hyperlipidemia was associated with an odds ratio of 0.57 (0.17, 1.90), which 
may be attributed to the fact that of the 21 patients with hyperlipidemia, 14 were on a 
statin and may have exhibited the potentially protective effects of statin treatment on 
fibrosis progression. Moreover, we found that an overweight BMI in the range of 25-29 
kg/m2 may have protective effects compared to the reference group with BMI of 30+ (OR 
0.45), while an underweight or average BMI may have detrimental effects on fibrosis 
progression compared to those with BMI of 30+. Although these results were not 
statistically significant, they may support the obesity paradox in chronic disease, which 
refers to an inverse association between excess adiposity and mortality. It has been 
demonstrated in a group of HIV-infected men who have sex with men, where those who 
were overweight possessed higher CD4 cell counts and lower viral loads than those of 
normal weight (100). Prospective studies will be needed to further assess the impact of 
metabolic derangements on the risk of fibrosis progression in the HIV/HCV co-infected 
population. 
 We hypothesized that a composite score of disease severity might be predictive of 
progression. The VACS Index generates a weighted score based on age, routinely 
monitored indicators of HIV disease (CD4 count and HIV-1 RNA) and general indicators 
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of organ system injury (hemoglobin, platelets, AST and ALT, FIB-4, creatinine, and 
HCV infection) to indicate increasing risk of all-cause mortality with increasing score 
(99). Not only does the VACS Index discriminate mortality risk more effectively than 
traditional indices restricted to CD4 count, HIV-1 RNA, and age, but it also predicts 
many other health outcomes in people living with HIV infection and has been validated 
in several European and North American cohorts (101, 102). The VACS Index has been 
shown to predict outcomes after admission for bacterial pneumonia, medical intensive 
care unit admission and fragility fractures, weight gain in the first 12 months after ART 
initiation, and acute myocardial infarction (103-109). We found that the VACS Index 
score differed significantly between progressors and non-progressors; however, the 
presence of Hepatitis C and the FIB-4 score which was the basis for our outcome 
variable, are included in the VACS Index calculation. A multivariate model that included 
all of the elements of the VACS Index except for Hepatitis C infection and FIB-4 score 
did not achieve statistical significance. 
There are several limitations to our study. The relatively small sample size might 
not have afforded us enough power to achieve statistical significance for the observed 
differences for variables that one would expect to show significance based on prior 
studies, including low CD4 count, high HIV viral load, diabetes, hyperlipidemia, and 
alcohol use disorder. An alternative explanation is that the HIV/HCV co-infected 
population is already at higher risk of fibrosis progression and cannot be further 
subdivided into increasing risk categories. Although FIB-4 has been well validated in 
HIV/HCV co-infected populations as an accurate method of assessing liver fibrosis, FIB-
4 values may fluctuate due to other comorbid conditions, both intrahepatic (hepatic injury 
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due to medications, alcohol, infections) and extrahepatic (sepsis, thrombocytopenia due 
to immune dysregulation or immune suppression), which may not truly reflect fibrosis 
severity. (33) In addition, our laboratory results were not restricted to those obtained in 
the outpatient setting and included some tests such as transaminases obtained during 
acute illness. However, we tried to mitigate the impact of FIB-4 fluctuations by taking the 
mean of 3 FIB-4 scores to obtain the annual FIB-4 score. Although it is possible that 
relying on a single non-invasive marker such as FIB-4 score to assess fibrosis severity 
may have influenced our findings, we found that the FIB-4 score showed strong 
concordance with liver biopsy stages in differentiating cirrhotic and non-cirrhotic patients 
out of the 38 patients who had ever received a liver biopsy. There were only 3 patients in 
our study with biopsy proven cirrhosis, and in 2 out of the 3 patients, the liver biopsies 
were obtained during the 5 year study period and corresponded to annual FIB-4 scores of 
4.10 and 7.31. The study was also limited by missing data. For example, the duration of 
HCV infection was only documented in a minority of patients, but this information would 
have been useful for determining whether those who progressed faster had been infected 
with HCV for a longer duration. 
Our study could also have been influenced by disease spectrum bias; those who 
progressed had higher mean FIB-4 scores at 5 years prior to study entry compared to non-
progressors (2.49 vs 1.73; Figure 1), and may have represented individuals with a longer 
duration of HCV infection. However, there was no statistically significant difference in 
age between the 2 groups which would make this bias less likely. Although most patients 
had been infected with HCV for well over a decade, the study duration was limited to 5 
years and may not have fully captured the natural history of fibrosis progression in this 
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population. Therefore, further observation over a longer duration of 10-15 years in a 
larger pool of patients may have detected smaller and more long-term effects.  
Data extracted from problem lists and chart review may not have completely 
captured variables such as alcohol use disorder; therefore, we also extracted information 
about AUDIT scores, which were routinely obtained at every outpatient visit. Yet it is 
possible that we underestimated the degree of alcohol intake. Our study was limited to 
patients receiving care at a single outpatient clinic and patients who were initially 
cirrhotic (FIB-4>3.25) were excluded, further reducing the sample size (N=93). 
 In conclusion, in this cohort of HIV/HCV-infected patients receiving care at a 
single clinic, based on FIB-4 score measurements, a quarter had significant fibrosis 
progression over a 5-year interval. There were no significant predictors of progression, 
although certain measures of HIV virologic control such as HIV viral load and CD4 
count at study entry tended to correlate with fibrosis progression.  
Our study cannot fully exclude the impact of these factors, and further research is 
needed to identify the factors that influence fibrogenesis through large, prospective 
natural history studies. It is notable that information from this study provides valuable 
insight into which variables should be utilized for testable hypotheses in future studies. 
What are the potential implications of our findings for prioritizing treatment with DAAs? 
While others might consider a “wait and see” approach feasible given that many patients 
in our study did not progress to cirrhosis based on FIB-4 scoring over 5 years, our 
findings did not identify any reliable predictors of fibrosis progression. Thus, universal 
treatment with DAAs would likely be the best approach and may be more readily 
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